The Tax Cuts and Jobs Act forced capitalization of research and experimental costs.

Now, the One Big Beautiful Bill (OB3) — through new §174A — restores options. But those options come with elections, deadlines, modeling decisions, and state-level complexity.

This is not just a compliance update.
It’s a cash flow, credit, and structural tax strategy decision.

What Changed?

Under TCJA:

• Domestic & foreign SREEs had to be capitalized.
• Domestic amortized over 5 years.
• Foreign amortized over 15 years.

Under OB3:

• Immediate deduction for domestic SREEs is back.
• Acceleration of remaining amortization is available.
• Retroactive deductions may apply (for eligible small businesses).
• Foreign SREEs still require 15-year capitalization.

Small Businesses: High Opportunity, High Complexity

Eligible Small Businesses (avg. gross receipts under $31M) may:

✔ Retroactively deduct 2022–2024 SREEs
✔ Accelerate remaining amortization into 2025 (100% or 50/50 split)
✔ Continue capitalization if preferred

But there are traps:

• It’s all-or-nothing for retroactive elections.
• Amended returns trigger K-1 updates and possible AAR filings.
  
• Refund timing may lag due to IRS processing delays.
• §280C coordination with the R&D credit becomes mandatory.

This is a modeling decision — not an automatic deduction play.

Larger Businesses: Strategic Acceleration Choices

For businesses above the gross receipts threshold:

• No retroactive deduction allowed.
• But acceleration of remaining basis is available in 2025.
• Election statements must be filed with the return.
• Three methods exist for new 2025 SREEs:
  
  1. Continue 5-year amortization
  2. Immediate deduction
  3. 10-year amortization under §59(e)

Once chosen, the method binds future treatment unless formally changed.

R&D Credit Interplay Just Got Tighter

OB3 ties qualified research under §41 directly to §174A.

That means:

• Method alignment is critical.
• §280C adjustments are mandatory going forward.
• Book-to-tax differences will increase scrutiny.

This is where poor planning creates permanent differences.

State Conformity: The Hidden Risk

Not all states follow OB3.

States like Maryland, Michigan, and Virginia have indicated non-conformity. That means:

• Federal deduction ≠ state deduction.
• Separate capitalization tracking may be required.
• Apportionment could drive unexpected adjustments.

Multi-state taxpayers must evaluate this carefully.

Strategic Takeaway

Section 174 is no longer a forced capitalization rule.
It’s now a strategic lever.

The real question is not “Can we deduct?”
It’s “When should we deduct — and what does that do to credits, NOLs, §163(j), and cash flow?”

Accelus Global works with growth-stage and enterprise taxpayers to model scenarios, align R&D credits with §174A methods, and structure defensible elections that optimize both tax position and compliance burden.

This is a planning window. It won’t stay open forever.